Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nantes Université RAD51 compound 23
- Development stage
- Unknown
- Lead developer
- Nantes Université
01
Overview
Nantes Université RAD51 compound 23: sourced facts only. name: "Three compounds, the cyano analogue (12), and benzamide (23) or phenylcarbamate (29) analogues of DIDS were characterized as novel potent RAD51 inhibitors with HR inhibition in the micromolar range." [PMID:36990245]; target: "Three compounds, the cyano analogue (12), and benzamide (23) or phenylcarbamate (29) analogues of DIDS were characterized as novel potent RAD51 inhibitors with HR inhibition in the micromolar range." [PMID:36990245]; developer: "Nantes Université, CNRS, US2B, UMR 6286, DNA-repair Group, F-44000 Nantes, France." [PMID:36990245]
02
Targets
RAD51 (RAD51 Recombinase)
Beyond the preview
Go deeper on Nantes Université RAD51 compound 23.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nantes Université RAD51 compound 23.